TL;DR
This study demonstrates that routine coronary function testing (CFT) during invasive coronary angiography (ICA) is safe, feasible, and significantly improves the quality of life for patients with angina and non-obstructive coronary arteries (ANOCA). By guiding treatment based on CFT results, patients experienced a greater reduction in angina symptoms compared to standard care.
What Problem Does This Paper Address?
Many patients experience angina (chest pain) even when their coronary arteries appear normal on standard angiography. This condition, known as angina with non-obstructive coronary arteries (ANOCA), affects a significant portion of patients undergoing cardiac workups. The underlying causes are often related to functional disorders of the coronary arteries, such as microvascular dysfunction or vasospasm, which are not detected by standard angiography alone. Current guidelines suggest using invasive coronary function testing (CFT) in these patients to identify these disorders and tailor treatment, but its routine use and clinical impact in a pragmatic setting are still being established. This paper addresses the question of whether implementing a routine, "ad hoc" (performed during the same procedure) CFT protocol during initial ICA, combined with a specific treatment strategy, can improve patient outcomes compared to standard care.
Methods
The ILIAS ANOCA trial was a prospective, randomized, blinded-arm controlled trial. Patients undergoing clinically indicated ICA who were found to have no obstructive coronary artery disease (CAD) were eligible. These patients then underwent "ad hoc" coronary function testing (CFT) during the same procedure. Following CFT, they were randomized 1:1 to either:
- Intervention Group: CFT results were disclosed, and patients received a tailored medical therapy protocol based on their specific ANOCA endotype (e.g., coronary microvascular dysfunction, vasospasm).
- Standard Care Group: CFT results remained blinded, and patients received standard care.
The primary outcome was the change in the Seattle Angina Questionnaire summary score (SAQSS) from baseline to 6 months. CFT involved assessing coronary flow reserve (CFR) and hyperemic microvascular resistance (HMR) using a guidewire after adenosine infusion, followed by acetylcholine provocation testing to assess for vasospasm.
Datasets
Not discussed in the paper. The study involved data collected from 153 patients undergoing invasive coronary angiography.
Key Insights and Ideas
- CFT is Safe and Feasible in Routine Practice: The study successfully integrated ad hoc CFT into routine ICA procedures without any reported complications or significant increases in procedure time, addressing a key barrier to its widespread adoption.
- High Diagnostic Yield for ANOCA: CFT identified a vasomotor disorder in a substantial majority (78%) of ANOCA patients, highlighting its crucial role in uncovering the underlying cause of symptoms.
- Tailored Treatment Drives Improvement: The most significant insight is that guiding medical therapy based on specific ANOCA endotypes identified by CFT leads to a clinically meaningful improvement in patient-reported quality of life and a reduction in angina symptoms.
- Pragmatic Approach Works: The study utilized a practical CFT protocol that did not require withholding vasoactive medications, making it more amenable to real-world clinical settings.
Key Results
- Improved Quality of Life: The intervention group showed a significantly greater improvement in the SAQSS compared to the control group, with an intervention effect of 9.4 units (95% CI 3.9–14.9, P = .001). This improvement was primarily driven by greater reductions in angina frequency and improvements in quality of life as assessed by the SAQ.
- Diagnostic Yield: A vasomotor disorder was identified in 120 out of 153 patients (78%) who underwent CFT. The most common diagnoses were isolated coronary spasm (42%) and combined coronary microvascular dysfunction (CMD) and spasm (20%).
- Safety: No major adverse cardiac events were reported at the 6-month follow-up, and CFT procedures were successfully completed in all patients.
- Medication Changes: Patients in the intervention group showed increased use of calcium channel blockers and short-acting nitrates, reflecting the tailored treatment approach based on CFT findings.
Limitations and Future Work
- Blinding: While the study was blinded regarding treatment allocation, it was impossible to fully blind patients and referring cardiologists to the CFT results, as these directly informed treatment decisions. However, the study team ensured blinding of CFT results to the intervention group's referring cardiologists.
- Patient-Reported Outcomes: The study relies on patient-reported outcomes, which are susceptible to bias.
- Formal Criteria vs. Symptomatic Treatment: The authors acknowledge that some patients with responses not fitting formal CFT criteria might still benefit from symptomatic treatment. Future analyses will focus on the impact of specific endotypes and responses to ACh testing, as well as endothelial function testing, on treatment response.
- Generalizability: While the study was conducted across multiple centers and included a diverse patient population, further research may be needed to confirm these findings in different healthcare systems.
Summary updated